Postdoctoral Research Associate

JOB DESCRIPTION

Inimmune Corporation has an exciting opportunity available immediately in our R&D Center for a postdoctoral research associate position in synthetic chemistry. Based in beautiful Missoula, MT, Inimmune’s mission is focused on the discovery and development of novel immunotherapeutics for the treatment of allergy,
cancer, autoimmune disorders and infectious diseases.

We are seeking candidates with a Ph.D. in Organic Chemistry or Medicinal Chemistry, and a strong background in multi-step organic synthesis. The successful candidate will work well in a team environment, demonstrate innovation in synthetic planning, and be highly motivated to help meet team driven goals.

Position Requirements:

The ideal candidate will have

  • a strong theoretical background and relevant laboratory experience in organic synthesis and modern purification and characterization techniques (NMR, HPLC, LC-MS, etc) with a solid understanding of medicinal chemistry and relevant biochemical disciplines.
  • technical proficiency and scientific creativity in one or more of the following areas; medicinal chemistry, multi-step synthesis, structure-activity relationship, lead compound discovery and development.
  • excellent oral and written communication skills and ability to effectively communicate with laboratory personnel, present data at internal and external meetings and contribute to writing of manuscripts, grants, technical reports and patents. Projects will involve cross-site project teams so the ability to work closely with co-workers and outside agencies and maintain confidentiality of sensitive information is essential.

Position Responsibilities:

The primary role of this position is to conduct the synthesis and structure-activity relationships (SAR) studies of novel small molecules or natural product-derived molecules. The ideal candidate will:

  • carry out multi-step synthesis, purification, and characterization of target compounds and intermediates on milligram to multi-gram scale.
  • troubleshoot and optimize existing chemical processes and assist with the design and implementation of new synthetic processes.
  • keep abreast of relevant scientific developments in organic synthesis and related fields by reading scientific literature and using database and library resources.
  • develop and maintain accurate and complete records of all laboratory activities in accordance with regulatory guidelines, standard operating procedures, and Inimmune requirements.
  • participate in appropriate departmental meetings, seminars, and project teams and perform research in a collaborative manner with other scientists and teams.
  • work independently and as part of a larger project team to design, execute and interpret experiments that contribute to the development and accomplishment of project strategies.
  • Comply with all Safety, Health and Environment policies and procedures.

Work Environment:

Inimmune has state-of-the-art R&D laboratories and equipment for drug discovery and development. The laboratory routinely uses general laboratory equipment such as vacuum pumps, DSC, chromatography purification systems, HPLC, rotovap, heating mantles, recirculating bath, laboratory glassware, analytical devices and chemical compounds. Our multi-disciplinary team is comprised of highly motivated, engaging professionals driven to provide breakthrough immunotherapies to patients. Our headquarters is located in beautiful Missoula Montana where our employees enjoy a high quality of life surrounded by a wide variety of recreational opportunities. Visit www.destinationmissoula.org to discover what we love about Missoula.

Inimmune offers a competitive compensation program including health care, dental, 401K and an incentive award program.

Apply on-line at: www.Inimmune.com or email directly to HR@Inimmune.com

Leadership, Innovation, Solutions, Inimmune Corp. is leading in the pursuit of novel immunotherapies and innovative vaccine formulations to battle the world’s most pervasive diseases.

Inimmune is an Equal Opportunity/Affirmative Action employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability, or protected Veteran status.

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics.

Contact

© Copyright 2022 Inimmune. All Rights Reserved.

Website Design by Digital Marketing Missoula
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.

TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING